Iyuzeh (Latanoprost/PF) Patent Expiration, LOE Window & CMS Spending

Iyuzeh (Latanoprost/PF) by Thea: Off-Patent Genericized (AB Competition), 0 AB generics, $7.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorThea
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$7.2M
2024 Medicare Part D Spend$6.7M
2024 Medicaid Spend$524K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel